產(chǎn)品詳情
簡(jiǎn)單介紹：
重組人干擾素-λ1/白細(xì)胞介素-29蛋白與其它公司提供的重組蛋白不同，rHuIFN-λ1/IL-29蛋白產(chǎn)品為采用CFS的無細(xì)胞麥胚蛋白合成系統(tǒng)表達(dá)出來的重組蛋白，可表達(dá)出對(duì)細(xì)胞有毒性、易被蛋白酶降解的蛋白；并獲得具有良好的可溶性，并有翻譯后修飾、從而部分具有功能的蛋白.同時(shí)獨(dú)有的全自動(dòng)蛋白純化技術(shù)則簡(jiǎn)便高效，將蛋白純化過程中對(duì)蛋白的損傷降低到*小程度.重組人干擾素-λ1/白細(xì)胞介素-29蛋白（全長(zhǎng)序列）產(chǎn)品可用于Western Blot驗(yàn)證、抗體制備、蛋白檢測(cè)、ELISA等試驗(yàn)中.
詳情介紹：
重組人干擾素-λ1/白細(xì)胞介素-29蛋白
| Synonyms | Cytokine Zcyto21 |
| Species | Human |
| Accession | Q8IU54 |
| GeneID | 282618 |
| Source | Escherichia coli. |
| Molecular Weight | 重組人干擾素-λ1/白細(xì)胞介素-29蛋白Approximately 19.8 kDa, a single non-glycosylated polypeptide chain containing 181 amino acids. |
| Quantity | 5μg/20μg/1000μg |
| AA Sequence | GPVPTSKPTT TGKGCHIGRF KSLSPQELAS FKKARDALEE SLKLKNWSCS SPVFPGNWDL RLLQVRERPV ALEAELALTL KVLEAAAGPA LEDVLDQPLH TLHHILSQLQ ACIQPQPTAG PRPRGRLHHW LHRLQEAPKK ESAGCLEASV TFNLFRLLTR DLKYVADGNL CLRTSTHPES T |
| Purity | > 97 % by SDS-PAGE and HPLC analyses. |
| Biological Activity | 重組人干擾素-λ1/白細(xì)胞介素-29蛋白Fully biologically active when compared to standard. The ED50 as determined by an anti-viral assay using human HepG2 cells infected with encephalomyocarditis is less than 5 ng/ml, corresponding to a specific activity of > 2.0 × 105 IU/mg. |
| Physical Appearance | Sterile Filtered White lyophilized (freeze-dried) powder. |
| Formulation | Lyophilized from a 0.2 μm filtered concentrated solution in PBS, pH 7.4. |
| Endotoxin | Less than 1 EU/μg of rHuIFN-λ1/IL-29 as determined by LAL method. |
| Reconstitution | 重組人干擾素-λ1/白細(xì)胞介素-29蛋白We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1 % BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at ≤ -20 °C. Further dilutions should be made in appropriate buffered solutions. |
| Storage | This lyophilized preparation is stable at 2-8 °C, but should be kept at -20 °C for long term storage, preferably desiccated. Upon reconstitution, the preparation is stable for up to one week at 2-8 °C. For maximal stability, apportion the reconstituted preparation into working aliquots and store at -20 °C to -70 °C. Avoid repeated freeze/thaw cycles. |
| 重組人干擾素-λ1/白細(xì)胞介素-29蛋白 | |
| Reference |
1. Miller EK, Hernandez JZ, Wimmenauer V, et al. 2012. Am J Respir Crit Care Med, 185: 508-16. 2. Li Y, Xie J, Xu X, et al. 2012. Protein Cell, 3. Jordan WJ, Eskdale J, Srinivas S, et al. 2007. Genes Immun, 8: 254-61. 4. Pekarek V, Srinivas S, Eskdale J, et al. 2007. Genes Immun, 8: 177-80. 5. Megjugorac NJ, Gallagher GE, Gallagher G. 2010. Blood, 115: 4185-90. |
| Background | IL-28A, IL-28B, and IL-29, also named interferon-λ2 (IFN-λ2), IFN-λ3, and IFN-λ1, respectively, are newly identified class II cytokine receptor ligands that are distantly related to members of the IL-10 family (11-13 % a.a. sequence identity) and the type I IFN family (15-19 % a.a. sequence identity). The expression of IL-28A, B, and IL-29 is induced by virus infection or double-stranded RNA. All three cytokines exert bioactivities that overlap those of type I IFNs, including antiviral activity and up-regulation of MHC class I antigen expression. The three proteins signal through the same heterodimeric receptor complex that is composed of the IL-10 receptor β (IL-10 Rβ) and a novel IL-28 receptor α (IL-28 Rα, also known as IFN-λR1). Ligand binding to the receptor complex induces Jak kinase activation and STAT1 and STAT2 tyrosine phosphorylation. |
